Keyphrases
Mayo Clinic
100%
BRAF V600E
100%
Metastatic Colorectal Cancer (mCRC)
100%
Metastasectomy
100%
Multimodality Approach
100%
Overall Survival
40%
Confidence Interval
40%
Hazard Ratio
30%
Oxaliplatin
20%
Liver
10%
Improved Survival
10%
Novel Treatments
10%
Fluoropyrimidine
10%
Colorectal Cancer
10%
Progression-free Survival
10%
Patient Selection
10%
Poor Prognosis
10%
Low-volume Metastasis
10%
Clinical Data
10%
Statistical Analysis
10%
Patient Characteristics
10%
Multidisciplinary Approach
10%
Platinum-based Chemotherapy
10%
Conventional Chemotherapy
10%
Combined Modality Therapy
10%
Disease-free Survival
10%
Survival Outcomes
10%
Bevacizumab
10%
Multivariate Analysis
10%
Clinical Characteristics
10%
Patient Utilization
10%
Molecular Data
10%
Fluorouracil
10%
Median Progression-free Survival
10%
Clinical Investigation
10%
Disease-free
10%
Leucovorin
10%
Irinotecan
10%
Median Overall Survival
10%
BRAF V600E mutation
10%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
10%
Log-rank Test
10%
Cox Proportional Hazards Model
10%
Author Experience
10%
Kaplan-Meier Method
10%
Clinical Survival
10%
Implications for Practice
10%
Wild-type KRAS
10%
Molecular Subset
10%
First-line Regimen
10%
Right-sided Tumors
10%
FOLFOXIRI Plus Bevacizumab
10%
Medicine and Dentistry
Metastatic Colorectal Cancer
100%
Metastasectomy
100%
Overall Survival
50%
Hazard Ratio
30%
Progression Free Survival
20%
Bevacizumab
20%
Oxaliplatin
20%
Neoplasm
10%
Oncology
10%
Metastatic Carcinoma
10%
Disease Free Survival
10%
Patient-Data
10%
Patient Characteristics
10%
Colorectal Carcinoma
10%
Irinotecan
10%
Multivariate Analysis
10%
Proportional Hazards Model
10%
Kaplan Meier Method
10%
Log Rank Test
10%
Folinic Acid
10%
Fluorouracil
10%
Fluoropyrimidine
10%
Diseases
10%